Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145).

The effects of Soto's 'beta-sheet breaker peptide' and its polymer on PrPSc formation in ScN2a cells were investigated. Surface plasmon resonance study indicated that direct binding between PrP(81-145) and the 'beta-sheet breaker peptide' is not specific and may not play a major role in the inhibition of PrPSc formation.

[1]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[2]  F E Cohen,et al.  Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Grubbs,et al.  Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. , 1999, Organic letters.

[4]  B. Caughey,et al.  Potent Inhibition of Scrapie‐Associated PrP Accumulation by Congo Red , 1992, Journal of neurochemistry.

[5]  S. Prusiner,et al.  Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form , 2001, The EMBO journal.

[6]  T. Wisniewski,et al.  Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.

[7]  G. Forloni,et al.  Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. , 1994, The Journal of biological chemistry.

[8]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[9]  F. Heppner,et al.  Interventional strategies against prion diseases , 2001, Nature Reviews Neuroscience.

[10]  T. Kinumi,et al.  Multi-valent polymer of vancomycin: enhanced antibacterial activity against VRE , 1999 .

[11]  B. Chesebro,et al.  Specific Inhibition of in Vitro Formation of Protease-resistant Prion Protein by Synthetic Peptides* , 1998, The Journal of Biological Chemistry.

[12]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[13]  B. Caughey,et al.  Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.

[14]  S. Prusiner,et al.  Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity , 1996, Science.

[15]  R. Grubbs,et al.  Synthesis of Functionalized Olefins by Cross and Ring-Closing Metatheses , 2000 .

[16]  C. Masullo,et al.  Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. , 1987, The Journal of general virology.

[17]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Cohen,et al.  Molecular properties of complexes formed between the prion protein and synthetic peptides. , 1997, Journal of molecular biology.

[19]  Tomoya Kinumi,et al.  Affinity of a vancomycin polymer with bacterial surface models , 2001 .

[20]  W. Caughey,et al.  Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.